F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

por Davis, Robert, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Vanover, Kimberly
Publicado 2018

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

por Vanover, Kimberly, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Davis, Robert
Publicado 2018

S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL

por Hassman, Howard, Cohen, Elan, Walling, David, Wyka, Katarzyna, Grindell, Vera, Glass, Steven, Ball, Roberta, Styczynski, John, Lobb, Jaclyn, Hazzard, Dakota, Joseph, Ashok, Ereshefsky, Larry
Publicado 2020